Ben Lamm's Colossal Biosciences Eyes $20B-$30B Valuation as De-Extinction Startup Diversifies Revenue
Colossal, the five-year-old firm behind projects to “resurrect” extinct species, is building out revenue streams through conservation tech and multiple spin-off ventures.
By Ryan Merket · Published
Primary source: TechCrunch
Why it matters
This potential valuation jump for Colossal Biosciences demonstrates how deep tech companies can leverage ambitious, long-term scientific goals to incubate commercially viable technologies and diversify revenue, attracting significant capital even before core de-extinction efforts yield immediate returns.
Colossal Biosciences, the company co-founded and led by Ben Lamm, is reportedly in talks to raise new capital at a valuation between $20 billion and $30 billion. The potential funding round would double or triple the de-extinction startup's previous valuation of $10.2 billion, which it secured in January 2025.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.